Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer (NCT07707674)
A Phase I, Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of XNW28012 Monotherapy in the Treatment of Subjects With Metastatic Pancreatic Cancer
🩺 Plain-English Summary (8th-Grade Level)
A Phase I, Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of XNW28012 Monotherapy in the Treatment of Subjects with Metastatic Pancreatic Cancer
Who can join: Review the eligibility criteria below.
Location: Karmanos Cancer Institute — Detroit, Michigan
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Karmanos Cancer Institute — Detroit, Michigan
- START - Midwest — Grand Rapids, Michigan
- START - New York Long Island — Lake Success, New York
- Cleveland Clinic Foundation — Cleveland, Ohio
- Oklahoma University Health Sciences Center — Oklahoma City, Oklahoma
- SCRI Oncology Partners — Nashville, Tennessee
- SCRI at Mary Crowley — Dallas, Texas
- START - San Antonio — San Antonio, Texas
📞 Contact the Study Coordinator
Phone: (562) 796-8006
Email: yingyi.zhang@evopointbio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Pancreatic Cancer
- Proglumide and Chemotherapy for Metastatic Pancreatic Cancer — Washington D.C., District of Columbia
- Saltikva for Metastatic Pancreatic Cancer — Montreal, Quebec
- Redefining FOLFIORINOX in Older Pancreatic Cancer Patients — Philadelphia, Pennsylvania
- Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy — New Hyde Park, New York
- Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. — Baltimore, Maryland
- Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer — Dallas, Texas
Explore by condition: All Metastatic Pancreatic Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.